A single dose of yttrium-90-labeled anti-CEA mAb, in combination with vaccine, statistically increased survival in tumor-bearing mice relative to vaccine or mAb therapy alone (Figure 3; Chakraborty et al., 2008a). This evidence concerns the gene CEACAM5 and neoplasm.